Related Experiment Video
Updated: Jul 2, 2025
04:28
Lung Tumor Cell Recruitment Assay
Published on: February 26, 2019
5.3K
Potential of the postoperative lymphocyte-to-monocyte and monocyte-to-red blood cell ratio in predicting locoregional
Joanna Grupińska1, Magdalena Budzyń2, Jakub Janowski3
1Chair and Department of Medical Chemistry and Laboratory Medicine, Poznan University of Medical Sciences, Poznan, Poland; Hospital Pharmacy, Greater Poland Cancer Centre, Poznan, Poland.
Advances in Medical Sciences
|February 23, 2024
Summary
Postoperative lymphocyte-to-monocyte ratio (LMR) and monocyte-to-red blood cell ratio (MRR) can predict breast cancer recurrence. Lower LMR and higher MRR indicate a shorter disease-free survival (DFS) in breast cancer patients.
Area of Science:
- Oncology
- Hematology
- Biomarkers
Background:
- Breast cancer is a leading cause of cancer mortality in women.
- Current biomarkers for predicting breast cancer prognosis are insufficient.
- Identifying novel prognostic markers is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the clinical significance of postoperative hematologic parameters in breast cancer patients.
- To determine the predictive value of specific hematologic ratios for disease recurrence.
- To investigate the association of these parameters with disease-free survival (DFS).
Main Methods:
- Retrospective analysis of 90 female breast cancer patients.
- Evaluation of postoperative hematologic parameters: LMR, MRR, NLR, PLR, LRR, PRR.
- ROC curve analysis for optimal cutoff values.
- Kaplan-Meier and Cox regression analysis for DFS association.
Main Results:
- Elevated postoperative monocyte count and MRR, and decreased LMR were observed in the recurrence group.
- Low LMR (≤3.044) and high MRR (>0.1398) were significantly associated with shorter DFS.
- 14% of patients had local, regional, or distant metastases.
Conclusions:
- Postoperative LMR and MRR are independent predictors of DFS in breast cancer.
- These hematologic ratios offer potential prognostic value for breast cancer patients.
- Further large-scale prospective studies are warranted for validation.
